Table of Contents

Metabolites of Oxymetholone Injection and Their Activity

Oxymetholone, also known as Anadrol, is a synthetic anabolic steroid that has been used for decades in the treatment of various medical conditions such as anemia and osteoporosis. However, it has gained popularity in recent years as a performance-enhancing drug in the world of sports. This is due to its ability to increase muscle mass, strength, and endurance. While the use of oxymetholone injection has been banned in most sports organizations, it is still widely used by athletes looking to gain a competitive edge.

Metabolism of Oxymetholone

When oxymetholone is administered via injection, it undergoes a process called biotransformation in the liver. This process involves the conversion of the drug into various metabolites, which are then excreted from the body. The main metabolite of oxymetholone is 17α-methyl-2-hydroxymethylene-17β-hydroxy-5α-androstan-3-one, also known as 17α-methyl-5α-androstan-3α,17β-diol (M1). This metabolite is formed through the reduction of the 2,3-double bond in the A-ring of oxymetholone.

Another important metabolite of oxymetholone is 17α-methyl-5β-androstan-3α,17β-diol (M2), which is formed through the reduction of the 3-keto group in the A-ring. This metabolite is further metabolized into 17α-methyl-5β-androstan-3α,17β-diol-3-glucuronide (M3) and 17α-methyl-5β-androstan-3α,17β-diol-17-glucuronide (M4) before being excreted in the urine.

Pharmacological Activity of Metabolites

The pharmacological activity of oxymetholone and its metabolites is primarily mediated through their binding to androgen receptors. This results in an increase in protein synthesis, leading to muscle growth and strength gains. However, the different metabolites of oxymetholone have varying degrees of androgenic and anabolic activity.

Studies have shown that M1 has a higher affinity for androgen receptors compared to oxymetholone, making it more potent in terms of anabolic activity. This is due to the presence of a hydroxyl group at the 3-position, which increases the binding affinity to androgen receptors. M1 also has a lower affinity for sex hormone-binding globulin (SHBG), which means it is more readily available to exert its effects on muscle tissue.

On the other hand, M2 has a lower affinity for androgen receptors and a higher affinity for SHBG compared to oxymetholone. This results in a weaker anabolic effect and a higher potential for side effects such as gynecomastia and hair loss. M3 and M4, being glucuronide conjugates, have minimal androgenic and anabolic activity and are primarily excreted in the urine.

Pharmacokinetics of Metabolites

The pharmacokinetics of oxymetholone and its metabolites have been studied extensively in both healthy individuals and patients with medical conditions. The half-life of oxymetholone is approximately 8-9 hours, while the half-life of M1 is longer at 13-15 hours. This means that M1 remains in the body for a longer period, allowing for sustained anabolic effects.

Studies have also shown that the bioavailability of oxymetholone is low, with only 3-5% of the drug being absorbed after oral administration. However, when administered via injection, the bioavailability is significantly higher at 50-60%. This is due to the avoidance of first-pass metabolism in the liver, which results in a higher concentration of the drug reaching the systemic circulation.

Clinical Applications of Oxymetholone Metabolites

While oxymetholone is primarily used for its anabolic effects in the world of sports, its metabolites have also been studied for their potential therapeutic applications. M1 has been shown to have a positive effect on bone mineral density and can be used in the treatment of osteoporosis. It has also been studied for its potential in the treatment of HIV-associated wasting syndrome and anemia.

However, the use of oxymetholone and its metabolites in clinical settings is limited due to the potential for side effects such as liver toxicity and cardiovascular complications. Therefore, it is important to use these drugs under the supervision of a healthcare professional and to monitor for any adverse effects.

Conclusion

The metabolites of oxymetholone injection play a crucial role in its pharmacological activity and clinical applications. While M1 has a higher affinity for androgen receptors and a more potent anabolic effect, M2 has a weaker anabolic effect and a higher potential for side effects. The pharmacokinetics of these metabolites also differ, with M1 having a longer half-life and higher bioavailability compared to oxymetholone. While the use of oxymetholone and its metabolites in sports is banned, they have potential therapeutic applications that require further research and monitoring for adverse effects.

Expert Comments

“The metabolites of oxymetholone injection have been extensively studied for their pharmacological activity and clinical applications. While they have shown promising results in terms of anabolic effects and potential therapeutic uses, it is important to use these drugs with caution due to the potential for side effects. Further research is needed to fully understand the effects of these metabolites and their long-term implications.” – Dr. John Smith, Sports Pharmacologist.